Vivos Therapeutics (VVOS) Income towards Parent Company (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Income towards Parent Company data on file, last reported at -$7.8 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 100.6% year-over-year to -$7.8 million in Q1 2026; TTM through Mar 2026 was -$25.1 million, a 122.38% decrease from a year earlier, with the FY2025 full-year figure at -$21.2 million, down 89.66% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$7.8 million, down from -$7.0 million in the prior quarter.
• Over the last five years, Income towards Parent Company for VVOS reached as high as $9.4 million in Q4 2023 and fell as low as -$7.8 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$3.8 million across 5 years, with a median of -$5.0 million in 2025.
• Across the five-year window, Income towards Parent Company jumped 251.35% in 2023 and plunged 159.74% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$6.2 million in 2022, then soared by 251.35% to $9.4 million in 2023, then plunged by 130.8% to -$2.9 million in 2024, then slumped by 141.04% to -$7.0 million in 2025, then decreased by 11.46% to -$7.8 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$7.8 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.4 million in Q3 2025.